This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Merrimack Pharmaceuticals To Present Preclinical Research On Five Novel Cancer Therapies

Stocks in this article: MACK

CAMBRIDGE, Mass., April 2, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that research data on five novel experimental cancer therapies (MM-398, MM-121, MM-111, MM-302, and MM-141) will be presented at the 2013 American Association for Cancer Research (AACR) Annual Meeting, April 6-10, 2013 in Washington, DC.  Presentations will include preclinical data evaluating the potential of treatments to restore tumor drug sensitivity and delay resistance when used alone or in combination with other targeted treatments.  Data will be shared in late-breaking sessions, mini-symposia and poster sessions.

"We are excited about the advancements and research to be presented regarding several of the therapies in Merrimack's robust oncology pipeline," said Ulrik Nielsen, PhD, Co-Founder and Chief Scientific Officer, Merrimack Pharmaceuticals. "The research explores the potential of our novel medicines to inhibit signaling to prevent tumor growth and improve responsiveness to treatments, as well as the potential of our investigational nanotherapeutics to deliver chemotherapy directly to diseased cells to enhance activity and improve safety. These therapies are being studied across multiple cancers such as head and neck, lung, breast, gastric, pancreatic and melanoma."

Late-Breaking Poster

  • Session Title: Late-Breaking Research - Clinical Research 1 LB-79: Combined treatment with HER3 antibody MM-121/ SAR 256212 and EGFR antibody cetuximab in pre-clinical models of head and neck cancer Monday, April 8, 2013, 1:00 PM - 5:00 PMHall A-C, Poster Section 45

Mini-Symposium Presentations

  • Session Title: Preclinical and Molecular Endocrinology in Hormone-Responsive Cancers 1072: MM-121/ SAR256212, an anti-ErbB3 antibody, restores sensitivity to letrozole and delays the onset of resistance in an ER+ breast cancer model Sunday, April 7, 2013, 4:05 PM - 4:20 PMRoom 206, Washington Convention Center
  • Session Title: Novel Targeted Therapies 2 4633: MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclinical models of gastric cancer Tuesday, April 9, 2013, 3:05 PM - 3:20 PMRoom 152, Washington Convention Center

Poster Sessions

  • Session Title: Experimental Combination Therapy 1 2077A: MM-141, a novel bispecific antibody co-inhibitor of IGF-1R and ErbB3, inhibits the proliferation of melanoma cells Monday, April 8, 2013, 1:00 PM -5:00 PMHall A-C, Poster Section 37
  • Session Title: Experimental Combination Therapy 2 3271: Tumor priming with cyclophosphamide increases delivery and activity of Her2-targeted liposomal doxorubicin (MM-302) in preclinical models of breast cancer Tuesday, April 9, 2013, 8:00 AM -12:00 PMHall A-C, Poster Section 37
  • Session Title: Novel Delivery Technologies 5622: The tumor microenvironment modulates the delivery and activation of liposomal encapsulated irinotecan, MM-398 Wednesday, April 10, 2013, 8:00 AM -12:00 PMHall A-C, Poster Section 41
  • Session Title: Antibody/Protein Therapeutics 5464: In-vitro studies of MM-121/ SAR 256212, an anti-ErbB-3 antibody, in combination with erlotinib in EGFR-wild-type NSCLC Wednesday, April 10, 2013, 8:00 AM -12:00 PMHall A-C, Poster Section 36

Sanofi and Merrimack entered into an exclusive, licensing and global collaboration agreement for MM-121 in 2009.

About Merrimack Pharmaceuticals, Inc.Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

Forward-Looking StatementAny statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

SOURCE Merrimack Pharmaceuticals, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs